Thérèse Croughs
Director/Board Member chez Bioxodes SA
Profil
Thérèse Croughs is a Non-Executive Director at Bioxodes SA. She was previously the Chief Medical Officer & Managing Director at Cytheris SA, a Clinical Project Leader at Bayer AG, and a Principal at Valerio Therapeutics SA from 2004 to 2013.
From 2015 to 2019, she served as the Chief Medical Officer at Neovacs SA. Dr. Croughs holds a doctorate degree from the Université Catholique de Louvain.
Postes actifs de Thérèse Croughs
| Sociétés | Poste | Début |
|---|---|---|
Bioxodes SA
 Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Director/Board Member | - |
Anciens postes connus de Thérèse Croughs
| Sociétés | Poste | Fin |
|---|---|---|
| NEOVACS | Chief Tech/Sci/R&D Officer | 01/06/2019 |
| BAYER AG | Corporate Officer/Principal | - |
| VALERIO THERAPEUTICS | Corporate Officer/Principal | - |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Chief Tech/Sci/R&D Officer | - |
Formation de Thérèse Croughs
| Université Catholique de Louvain | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BAYER AG | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| NEOVACS | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Health Technology |
